Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

被引:201
作者
Otocka-Kmiecik, Aneta [1 ]
Mikhailidis, Dimitri P. [2 ]
Nicholls, Stephen J. [3 ]
Davidson, Michael [4 ]
Rysz, Jacek [5 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland
[2] UCL, Sch Med, Dept Clin Biochem, London, England
[3] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[5] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
关键词
Dyslipidemia; High density cholesterol; Inflammation; Lipids; Therapy; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CHOLESTERYL ESTER TRANSFER; TRANSFER PROTEIN-INHIBITION; ELEVATED OXIDATIVE STRESS; TYPE-2; DIABETIC-PATIENTS; ACUTE CORONARY SYNDROMES; HIGH-RISK; ANTIINFLAMMATORY PROPERTIES; ANTIOXIDANT PROPERTIES;
D O I
10.1016/j.plipres.2012.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High density lipoprotein (HDL) has many properties, which contribute to its atheroprotective role. However, some recent clinical trials have identified subjects with the progression of atherosclerosis despite normal levels of HDL cholesterol. This raises the question if all subfractions of HDL have the same properties. Moreover, recent investigations have shown that both acute and chronic inflammation may lead to structural and functional changes of HDL, which render the particles proinflammatory. Although therapeutic agents that increase HDL levels are now quite well established it is not clear whether they influence HDL quality. We review the current state of knowledge on the properties of HDL and factors/therapeutic agents which may restrain the transformation of normal HDL into dysfunctional HDL (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:314 / 324
页数:11
相关论文
共 128 条
[61]   Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host [J].
Khovidhunkit, W ;
Kim, MS ;
Memon, RA ;
Shigenaga, JK ;
Moser, AH ;
Feingold, KR ;
Grunfeld, C .
JOURNAL OF LIPID RESEARCH, 2004, 45 (07) :1169-1196
[62]   Infection and inflammation-induced proatherogenic changes of lipoproteins [J].
Khovidhunkit, W ;
Memon, RA ;
Feingold, KR ;
Grunfeld, C .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 :S462-S472
[63]   Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage [J].
Kobayashi, J ;
Okamoto, H ;
Otabe, M ;
Bujo, H ;
Saito, Y .
ATHEROSCLEROSIS, 2002, 162 (01) :131-135
[64]   A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity [J].
Kontush, A ;
de Faria, EC ;
Chantepie, S ;
Chapman, MJ .
ATHEROSCLEROSIS, 2005, 182 (02) :277-285
[65]   Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress [J].
Kontush, A ;
Chantepie, S ;
Chapman, MJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) :1881-1888
[66]   Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? [J].
Kutter, D ;
Devaquet, P ;
Vanderstocken, G ;
Paulus, JM ;
Marchal, V ;
Gothot, A .
ACTA HAEMATOLOGICA, 2000, 104 (01) :10-15
[67]   Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome [J].
Lagos, K. G. ;
Filippatos, T. D. ;
Tsimihodimos, V. ;
Gazi, I. F. ;
Rizos, C. ;
Tselepis, A. D. ;
Mikhailidis, D. P. ;
Elisaf, Moses S. .
LIPIDS, 2009, 44 (01) :9-16
[68]   HDL metabolism in hypertriglyceridemic states: an overview [J].
Lamarche, B ;
Rashid, S ;
Lewis, GF .
CLINICA CHIMICA ACTA, 1999, 286 (1-2) :145-161
[69]   Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia [J].
Le Goff, W ;
Guerin, M ;
Chapman, MJ .
PHARMACOLOGY & THERAPEUTICS, 2004, 101 (01) :17-38
[70]   Inhibition of arterial thrombus formation by apoA1 Milano [J].
Li, DY ;
Weng, S ;
Yang, BC ;
Zander, DS ;
Saldeen, T ;
Nichols, WW ;
Khan, S ;
Mehta, JL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :378-383